Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effectiveness of sovateltide, a new drug candidate, in treating patients with acute cerebral ischemic stroke. This type of stroke occurs when a blood clot blocks blood flow to the brain, causing damage to brain cells. The study builds on earlier clinical trials in India that showed promising results in improving neurological function and recovery with sovateltide, encouraging further testing in the United States and other countries. The trial compares sovateltide combined with standard care against a placebo normal saline plus standard care. Participants will receive three intravenous doses of sovateltide or placebo on days 1, 3, and 6 after stroke onset. Each dose is given as a one-minute IV bolus within 24 hours of stroke symptoms beginning. The study is randomized, double-blind, and placebo-controlled to rigorously assess the treatments impact. Participants will be monitored for 90 days after receiving treatment. Researchers will use several scales to evaluate recovery, including the modified Rankin Scale to measure disability, the National Institutes of Health Stroke Scale for neurological function, and the Barthel Index for daily living activities. Quality of life assessments and cognitive tests will also be done. Safety is closely watched for any adverse events or complications during the study period. The total participation time is about three months following treatment.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of subcutaneous immunotherapy SCIT in people aged 12 to 65 who have allergic rhinitis or rhinoconjunctivitis, with or without mild to moderate asthma. The study focuses on patients sensitized to specific house dust mites, Dermatophagoides pteronyssinus andor Dermatophagoides farinae. This is a phase 3, double-blind, placebo-controlled, randomized trial conducted at multiple centers. Participants will be randomly assigned to one of three groups two receive different doses of SCIT 10,000 TUmL or 30,000 TUmL of allergenic extract, and one receives a placebo injection without active ingredients. Treatment lasts for one year, with doses administered subcutaneously. The study compares the two active treatment groups to the placebo group to determine which dose may be more effective and safe. During the trial, participants will be closely monitored for symptoms and medication use, assessed by the Combined Symptoms and Medication Score CSMS over 12 months. Researchers will also track medication-free days, symptom-free days, quality of life related to asthma and rhinitis, adverse events, and immunological responses. Participants will log symptoms and medication use via smartphone. Safety and treatment effects will be evaluated throughout the study period.
Actively Recruiting
Researchers are evaluating whether EP-088MM09, which contains modified house dust mite allergens called mannan-conjugated allergoids, can treat house dust mite allergy and how safe it is. The trial involves people aged 12 to 65 years who have persistent moderate to severe nasal allergy symptoms, with or without eye symptoms, and may have mild to moderate controlled allergic asthma. The study compares EP-088MM09 with a placebo to see if it reduces allergy symptoms and the need for symptom-relief medicines. Participants are randomly assigned to receive either EP-088MM09 or a placebo, which looks the same but contains no active ingredients. The treatment includes 12 monthly visits with injections under the skin two injections at the first visit and one injection at each subsequent visit. Participants stay at the clinic for at least 30 minutes after each injection. Those sensitive to pollen may have an extra baseline visit to avoid pollen season influence. The study includes a screeningbaseline phase, treatment phase, and a final follow-up about one month after the last treatment. During the study, participants will keep daily records of their symptoms and medication use and complete questionnaires about their symptoms and quality of life. Blood samples will be collected at scheduled visits. Researchers will assess the combined symptom and medication score over multiple periods, including a main evaluation covering four weeks after treatment ends. Participants will be involved for about 14 to 21 months, with regular monitoring of health and treatment adherence throughout.